title: The evi5 oncogene regulates cyclin accumulation by stabilizing the anaphase-promoting complex inhibitor emi1.
abstract: The anaphase-promoting complex/cyclosome (APC/C) inhibitor Emi1 controls progression to S phase and mitosis by stabilizing key APC/C ubiquitination substrates, including cyclin A. Examining Emi1 binding proteins, we identified the Evi5 oncogene as a regulator of Emi1 accumulation. Evi5 antagonizes SCF(betaTrCP)-dependent Emi1 ubiquitination and destruction by binding to a site adjacent to Emi1's DSGxxS degron and blocking both degron phosphorylation by Polo-like kinases and subsequent betaTrCP binding. Thus, Evi5 functions as a stabilizing factor maintaining Emi1 levels in S/G2 phase. Evi5 protein accumulates in early G1 following Plk1 destruction and is degraded in a Plk1- and ubiquitin-dependent manner in early mitosis. Ablation of Evi5 induces precocious degradation of Emi1 by the Plk/SCF(betaTrCP) pathway, causing premature APC/C activation; cyclin destruction; cell-cycle arrest; centrosome overduplication; and, finally, mitotic catastrophe. We propose that the balance of Evi5 and Polo-like kinase activities determines the timely accumulation of Emi1 and cyclin, ensuring mitotic fidelity.
authors.affiliation: Department of Cancer Biology, Stanford University School of Medicine, CA 94305, USA.
authors.forename: Adam G
authors.initials: AG
authors.lastname: Eldridge
authors.forename: Alexander V
authors.initials: AV
authors.lastname: Loktev
authors.forename: David V
authors.initials: DV
authors.lastname: Hansen
authors.forename: Emmy W
authors.initials: EW
authors.lastname: Verschuren
authors.forename: Julie D R
authors.initials: JD
authors.lastname: Reimann
authors.forename: Peter K
authors.initials: PK
authors.lastname: Jackson
mesh_terms: D000705:Anaphase / Q000502:physiology*; D064173:Anaphase-Promoting Complex-Cyclosome; D000818:Animals; D002453:Cell Cycle / Q000502:physiology; D018797:Cell Cycle Proteins / Q000378:metabolism* / Q000494:pharmacology; D002460:Cell Line; D019925:Cyclin A / Q000378:metabolism*; D044783:F-Box Proteins; D020690:GTPase-Activating Proteins; D006367:HeLa Cells; D006801:Humans; D007399:Interphase; D008954:Models, Biological; D009687:Nuclear Proteins / Q000235:genetics / Q000378:metabolism*; D010766:Phosphorylation; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D044843:SKP Cullin F-Box Protein Ligases / Q000378:metabolism; D020798:Two-Hybrid System Techniques; D043743:Ubiquitin-Protein Ligase Complexes / Q000037:antagonists & inhibitors / Q000378:metabolism*; D014981:Xenopus; D000097869:Polo-Like Kinase 1
chemical_list: D064173:Anaphase-Promoting Complex-Cyclosome; D018797:Cell Cycle Proteins; D019925:Cyclin A; D044783:F-Box Proteins; D020690:GTPase-Activating Proteins; D009687:Nuclear Proteins; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D044843:SKP Cullin F-Box Protein Ligases; D043743:Ubiquitin-Protein Ligase Complexes; D000097869:Polo-Like Kinase 1; C506399:EVI5 protein, human; C498960:FBXO5 protein, human